Peptide Payment Processors and Merchant Accounts for UK and EU Sellers

If you sell peptides online in the UK or the EU, a mainstream processor has probably already closed you, or will. Stripe, PayPal, Square and Shopify Payments let peptide sellers sign up in minutes. Their risk teams then find the store weeks or months later, and the account goes, often with funds held.

Peptide sellers can take card payments. It takes a specialist merchant account, underwritten before you trade rather than after. What you sell, how you describe it and who buys it decide the outcome far more than the word "peptide" does.

If you sell collagen or other mainstream supplements without research-use positioning, the underwriting is closer to supplement retail, and we cover it on a separate page. See our guide to supplement merchant accounts.

Specialist payment routes for peptide businesses

There are four realistic routes to taking payments as a UK or EU peptide seller. They differ in stability, cost and what they will accept, so the right one depends on your product range rather than on who says yes first.

We do not publish a named league table for this vertical. Acquirer appetite for peptides moves, and it depends on the exact products and wording, so a list of names would mislead more sellers than it helped.

No route approves every peptide business. In practice, the same acquirer can accept one seller's research-use catalogue and decline another's because of how the website describes it.

What a specialist account gives you that Stripe or Shopify Payments cannot

The difference is when the risk assessment happens. Mainstream processors check you after you have started trading. Specialists check you before the account opens.

A mainstream account that works today is not evidence it will work next month. It usually means the risk review has not happened yet.

So optimise for stability over headline rate. A slightly higher rate on an account that lasts costs far less than a cheap account that freezes a month of revenue.

What to check before you sign

Approval is not the finish line. The terms decide whether the account works commercially, so ask these questions of any offer.

The avoidable mistakes we see most often:

• Signing for the lowest rate. The cheapest quote often carries the heaviest reserve or the tightest monitoring.
• Declaring a narrower range than you sell. Leaving out a product line to get approved sets up a closure later.
• Ignoring chargeback tooling. Without dispute alerts and 3D Secure, one bad month can end the account.
• Skipping the contract terms on termination. Know the notice period and hold period before you need them.

What a peptide payment processor actually is

Yes, a UK or EU peptide business can accept card payments online. It needs an acquirer whose policy covers the products, and a website and evidence pack that pass underwriting.

"Payment processor" gets used loosely. Several parties sit behind a single card payment, and knowing which one makes the decision saves wasted applications.

A high-risk merchant account is the same product with deeper underwriting. Expect more questions at application, higher pricing, a reserve, and closer monitoring once you are live.

The real split is between dedicated and shared accounts:

• Aggregator accounts are shared. Stripe, PayPal and Square put thousands of sellers under one master account. Onboarding is instant because nobody reviews you properly first.
• Aggregators remove risk fast. When their automated checks flag a peptide store, the cheapest option for them is to close it.
• Dedicated accounts are yours. You are underwritten as an individual business. The acquirer has agreed to your risk before you take a payment.
• Dedicated accounts are harder to get. That is the point. The difficulty up front is what makes the account stable later.

Subscriptions and selling across the UK and EU

Recurring billing is possible for peptide sellers, but it raises the bar. Subscriptions generate more disputes, so acquirers look harder at cancellation and renewal notices.

Selling across borders works differently. Your approval covers the countries you declared, and peptide rules vary sharply by destination. Shipping to a new country without telling your acquirer is a common trigger for a review.

One EU acquirer can cover several countries. An acquirer licensed in one member state can usually process for merchants across the EU. That does not make a product lawful in every country it ships to.

Rules differ between member states. A product sold openly in one EU country can be restricted in the next. Acquirers check your list of destination countries against your catalogue.

UK to EU is cross-border. Since Brexit, a UK seller shipping into the EU faces customs checks, and seized parcels turn into disputes. EU sellers shipping to the UK face the same in reverse.

Multi-currency acceptance is widely available. Check the settlement currency, because conversion costs on every payout add up quickly.

What peptide payment processing costs

Specialist processing costs far more than mainstream retail. Peptide rates typically run 5% to 10% per transaction, against 1.5% to 2.5% on a mainstream account, because the acquirer is pricing in dispute exposure and a heavier compliance review.

Where you land in that range depends on your business. The biggest factors:

• Your product catalogue. Cosmetic and collagen ranges price lower than research-use catalogues.
• Startup or established. A new business with no processing history is priced towards the top of the range.
• Processing volume. Sellers processing high, steady volumes with clean dispute history negotiate towards the bottom.
• How the business is run. Website compliance, fulfilment and refund handling all feed into the price.

The headline rate is only half the picture. For many peptide sellers, the reserve decides whether the account works commercially.

Treat those as category guidance, not quotes. Rates really do depend on the business. Two peptide sellers with similar turnover can be priced very differently because their catalogues and websites read differently to an underwriter.

Where sellers most often misread a quote:

• Reserve is cashflow, not a fee. A 10% reserve held for 180 days means six months of that slice of revenue sitting with the acquirer before the first release.
• Blended rates hide the card mix. A single percentage looks tidy but hides what corporate and cross-border cards actually cost.
• Monthly minimums bite in quiet months. Fall below the minimum and you pay for processing you did not use.
• Chargeback fees compound. At £25 a case, a 1% dispute rate on 2,000 orders a month costs £500 before the lost stock.

Our own service works differently. Advice is free, and in almost every case the seller pays us nothing. Where an application needs substantial work, a setup fee can apply, and we set it out in writing before anything is submitted.

How peptide merchant account approval works

Underwriters review you. They do not simply process a form. We regularly see applications fail on presentation when the business behind them was placeable.

Expect two to six weeks from a complete application to live processing. Cosmetic and collagen ranges with clean history sit at the short end. Research-use catalogues, prior closures and prescription medicines take longer.

1. Pre-assessment. A broker or acquirer reviews your product list and website before a formal application.
2. Application. Company, ownership and trading documents go in, with the full catalogue.
3. Underwriting review. The acquirer checks products, claims, suppliers and history, and usually comes back with questions.
4. Website review. The live site is checked against what you declared.
5. Contract and integration. Pricing and reserve are agreed, then the gateway is connected and tested.

Be realistic about the odds. Some peptide businesses cannot be placed at all, usually because of what they sell rather than how they apply. It is better to hear that before an application than after three declines.

What underwriters actually assess:

• The legal entity and its people. Company standing, directors, beneficial owners and anything attached to them.
• The products and their intended use. Every line, and whether the use you declare matches how you sell it.
• How the website presents them. Imagery, product copy, reviews and anything implying human use.
• The supply chain. Where products come from and whether you can evidence what is in them.
• Processing history. Previous statements, dispute ratios and any prior closures.

The evidence underwriters ask for

Assembling this pack before you apply is the single biggest thing you can do to shorten the timeline. Incomplete packs cause more delay than anything else we see.

• Company documents. Certificate of incorporation, plus identity and address checks for directors and beneficial owners.
• Bank and processing statements. Usually three to six months, including from any account that was closed.
• Full product catalogue. Every line, with the intended use declared for each one.
• Labels and listings as customers see them. Screenshots or access to the live site, not a tidied-up version.
• Supplier details and batch certificates of analysis. Evidence of what is in each product and where it came from. Our guide to peptide testing in the UK covers what a credible certificate looks like.
• Live website policies. Terms, refund, delivery and cancellation pages, plus age checks where relevant.
• Regulatory registrations where they apply. For prescription medicines, GPhC pharmacy registration in the UK or your national pharmacy licence in the EU, plus your prescriber arrangements. For cosmetics, your UK or EU Responsible Person details.

Why peptide applications get declined

A common issue is that sellers treat a decline as a verdict on the business. Usually it is a verdict on the application, and most causes can be fixed.

• Research-use labels contradicted by the website. Dosing guides, injection tutorials, before-and-after photos or customer reviews describing personal use.
• Undisclosed product lines. The underwriter finds products on the site that were not in the application.
• Prescription medicines with no pharmacy framework. GLP-1 products offered without a registered pharmacy and prescriber.
• An undisclosed prior closure. Previous terminations surface in checks, and hiding one is treated far worse than disclosing it.
• No evidence of what is in the product. Missing supplier documents or certificates of analysis.

What improves your chances

The actions that improve approval odds are unglamorous, and all of them happen before the application goes in:

• Audit the website against your declared use. Every page, product description and image should tell the same story as your application.
• Disclose everything. Every product, every country and every previous account.
• Have the evidence ready. Batch certificates and supplier documents on file before you are asked for them.
• Apply where appetite exists. Scattering applications across acquirers that do not take peptides leaves a trail of declines.

Why Stripe, PayPal, Shopify Payments and Square close peptide sellers

Most peptide sellers start on a mainstream processor because signup is instant and free. The problem is that instant signup means nobody has actually approved the business yet.

These aggregators onboard first and review later. Their acceptable use policies restrict pharmaceuticals and products sold with health claims, and their risk teams apply that to peptides.

What a closure typically looks like is a short email and an immediate stop on payouts. Appeals rarely reverse it, because the decision is about the category rather than your conduct.

Easy onboarding and durable fit are different things. A mainstream account is a trial period that ends when the risk team finds you. Marketplaces take the same line, as we explain in can you sell peptides on TikTok Shop?

Why peptide businesses are underwritten as high risk

High risk is a pricing and underwriting category, not a judgement on your business. Plenty of well-run peptide sellers carry the label. It comes from four things acquirers cannot fully control.

The research-use gap. Many peptides are sold "for research use only", while some customers buy them to use personally. Acquirers know this, so they read your website for signs of which one you are really serving.

Medicines regulation risk. Some peptides are licensed medicines and others sit close to that line. A product that counts as a medicine brings regulator attention, and acquirers do not want to be the bank processing it.

Card scheme reputation risk. Visa and Mastercard hold acquirers responsible for the merchants they sign. Health products with a history of enforcement action draw extra scrutiny from the schemes themselves.

Chargeback patterns. Disputes come from efficacy complaints, delivery delays, customs seizures and forgotten subscriptions. Each one costs the acquirer if the seller cannot cover it.

Your Merchant Category Code, the code that tells the card schemes what you sell, carries these risks with it. A peptide seller placed under the wrong code tends to be found and reclassified, which usually means a review or closure.

What seems true on paper is that a compliant seller is a low-risk seller. In practice, acquirers price the whole category, then adjust for how well you evidence that you are the compliant end of it.

Account closures, frozen funds and getting back to trading

This is where the real damage happens. Most sellers survive the closure itself. What puts them out of business is losing access to weeks of settlement while suppliers still need paying.

Funds in flight do not disappear, but they stop moving. Expect a hold covering the chargeback window, commonly 90 to 180 days from the last transaction.

Closures rarely arrive without cause, though they often arrive without warning. What usually comes first:

• A dispute ratio breach. One bad month is often enough. It does not need to be a trend.
• A catalogue change. Adding a product line the acquirer never approved triggers a fresh assessment.
• Volume far above forecast. Process several times your projection and you get a review, not a congratulatory call.
• A website that drifted. Copy, imagery or reviews that no longer match the use you declared.

What to do, in order, after a closure:

1. First 48 hours: get the reason in writing. The next acquirer will ask, and a documented reason beats a vague one.
2. First week: reconcile what is held. Get the held amount and release date in writing so you can plan against a real figure.
3. First week: tell customers before payments fail. A short, honest message keeps far more of them than a declined card does.
4. Weeks one to four: apply to a specialist with full disclosure. Include the closure and what you have changed since.
5. Months three to six: watch the release. Held funds are released on the schedule you were given, less any disputes.

Prior closures are not disqualifying. Specialist acquirers see them all the time and care far more about what changed. Having one discovered later is considerably worse than disclosing it.

How do you avoid being shut down in the first place? Get underwritten properly, keep the website consistent with what you declared, and run a second route. Sellers who have been through one closure often keep a backup account with a different acquirer, so a single risk decision cannot stop the business trading.

Chargebacks, reserves and keeping the account stable

Getting approved is the easy half. Staying approved comes down to two numbers: your dispute ratio and the reserve your acquirer holds against it.

Card schemes run monitoring programmes that count disputes against transactions. The commonly cited threshold sits around 1%, but most acquirers act well before it, because by then they are already exposed.

What tends to happen as the ratio climbs:

• Below 0.5%. Normal territory. Nobody calls.
• 0.5% to 0.9%. The account is watched. Expect a conversation and possibly a reserve increase.
• 0.9% to 1%. Remediation plans, tighter terms and fraud tooling you can no longer opt out of.
• Above 1%. Scheme monitoring programmes, fines passed through by the acquirer, and closure as a real possibility.

Peptide disputes cluster in predictable places:

• Customs seizures. The parcel never arrives, and the customer disputes rather than waits.
• Delivery delays. Long transit on cold-chain or imported stock turns into "item not received".
• Efficacy complaints. The customer expected a result and found the bank easier than your support inbox.
• Unrecognised descriptors. The name on the statement does not match the store they bought from.

Reserves come in three shapes, and the shape matters more than the percentage:

• Rolling reserve. A percentage of each day's settlement held for a fixed period, then released on a rolling basis.
• Capped reserve. Held until a fixed total is reached, then no further deductions. Better for growing sellers.
• Up-front reserve. A deposit paid at the start. Painful on day one, but it leaves daily cashflow alone afterwards.

The mitigations that actually move the number are mundane:

• Ship with tracking and share it. Delivery evidence wins the disputes worth defending.
• Fix the billing descriptor. It should match the brand the customer thinks they bought from.
• Refund fast. A quick refund costs less than a chargeback and does not count against your ratio.
• Use 3D Secure. Turning it off to lift conversion moves the cost of fraud onto you.
• Use dispute alerts. Early warning lets you refund before a dispute becomes a chargeback.

Most sellers assume their dispute rate is a fraud problem. More often it is a delivery and communication problem.

Which peptide products can be placed, and on what terms

"Peptides" is not one category to an acquirer. Research reagents, cosmetic peptides, collagen supplements and prescription medicines are underwritten differently, and the difference decides whether you can be placed at all.

The points sellers most often get wrong:

• A research-use label is not a shield. "Not for human consumption" on the vial does not make a sale lawful or placeable if the rest of the website says otherwise.
• Consistency is what gets approved. The label, product page, imagery, reviews and marketing all have to support the same intended use.
• Prescription-only means prescription-only. Semaglutide and tirzepatide are prescription-only medicines in the UK and across the EU. We can only help pharmacies selling them through a proper prescribing framework.
• Some businesses cannot be placed. Selling research-grade GLP-1 compounds for personal use, or prescription medicines without a prescription, falls outside what any legitimate acquirer will accept.
• Mixed catalogues are judged by their riskiest line. One product outside appetite can sink an otherwise placeable application.

Legal-to-sell and approved-to-process are different tests. A product can be lawful and still fall outside an acquirer's appetite, and compliance problems usually surface at underwriting or at a later account review.

The full legal position on selling peptides in the UK or any EU country is a bigger question than payments. We cover the UK side in is it legal to sell peptides in the UK? Take legal advice on your specific products, and do not rely on this page as legal guidance.

Selling from the UK or EU: what US guides get wrong

Most of what ranks for peptide payments is written for American sellers. Some of it does not apply to you, and following it can waste months.

LegitScript certification. Do you need LegitScript to accept payments for peptides? Not as a UK or EU rule. It is a US-based certification that some acquirers ask for, mainly when you sell into the US or into pharmacy categories.

FDA status. US guides talk about FDA approval. In the UK, the regulator for medicines is the MHRA. In the EU, it is the European Medicines Agency alongside each country's national regulator.

ACH and eCheck. These are US bank payment rails. The UK and EU equivalents are open banking, bank transfer and SEPA payments.

Crypto, open banking and bank transfer as secondary options

Can peptide businesses accept card and crypto payments? Yes, and running both is sensible. Alternative methods work best alongside cards, not instead of them.

• Open banking. The customer pays straight from their bank app. There are no card chargebacks, but conversion depends on customers being comfortable with it.
• Bank transfer. Cheap and dispute-free, but slow and manual. It suits repeat and trade buyers more than first-time customers.
• Crypto settlement. Some sellers use it as a backup. Expect lower take-up and your own tax and compliance checks.
• Removing cards costs sales. Many customers abandon a checkout with no card option, so treat alternatives as a safety net.

Alternative methods still carry compliance checks of their own. Open banking and crypto providers screen merchants too, so a product outside card appetite is often outside theirs as well.

Mistakes that get peptide merchants closed

Most closures we see were avoidable. They follow a small number of patterns. If you are still planning your launch, our guide on how to start a peptide business in the UK covers the steps before payments.

Starting on a mainstream processor and hoping. It works until the review, then it costs you a month of revenue.

Mixing research-use labels with human-use marketing. An injection guide on the blog undoes a compliant label on the vial.

Expanding without telling the acquirer. New product lines or new countries after approval are a common trigger for a review.

Letting chargebacks drift. Nobody watches the ratio until the acquirer calls about it.

Relying on one route. A single account means a single risk decision can stop the business trading.

How Merchant Advice helps peptide businesses get placed

We are an independent broker, not a payment provider or an affiliate. Our job is to get your application in front of acquirers that will genuinely consider it, in a state they can approve.

• Pre-assessment first. We review your catalogue and website before anything is submitted, and tell you what an underwriter will flag.
• Matching on written appetite. We approach UK and EU acquirers that accept your product type, not every acquirer on the market.
• Evidence pack preparation. We help you assemble the documents that shorten underwriting.
• A straight answer when it is a no. If your range cannot be placed, we will say so rather than burn applications.
• Transparent fees. Advice is free. Where a setup fee applies, you get it in writing before anything is submitted.

Conclusion

Peptide sellers can take card payments reliably. It takes an account underwritten before you trade, with an acquirer whose appetite covers your exact products.

Product type decides what is possible. Research-use, cosmetic and supplement ranges can be placed when the evidence and website line up. Prescription medicines need a regulated pharmacy behind them.

The sellers who stay live are the ones who disclose everything, keep their website consistent with their application, and run more than one route.